FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910443668> ?p ?o ?g. }

• W2910443668 endingPage "20" @default.
• W2910443668 startingPage "11" @default.
• W2910443668 abstract "The covalent binding of proteins with polyethylene glycol (PEG) molecules is a valuable tool to extend the half-life of many biotherapeutics, including factor VIII (FVIII) products to treat patients with haemophilia A. Although PEG has low toxicity, accumulation of large PEG molecules (>20-30 kDa) with long-term exposure is a potential concern. Thus, it is important to determine whether sufficient excretion processes exist for PEG molecules used in biotherapeutics. BAY 94-9027 is an extended-half-life FVIII product modified through addition of a 60-kDa (branched: dual 30-kDa) PEG molecule. BAY 1025662 is the 60-kDa PEG moiety used for PEGylation of BAY 94-9027. This study investigated the pharmacokinetic (PK) properties, distribution, and excretion of BAY 1025662 in rats in order to predict estimated 60-kDa PEG PK properties in patients. Plasma concentrations in male rats after a single 11-mg/kg intravenous dose of BAY 1025662 (approximating the cumulative PEG-60 exposure in patients during 30 years of BAY 94-9027 treatment) decreased with an initial half-life of 119 h (5 days) in the interval of 114-336 h post administration. Single-dose mass balance studies using radiolabeled BAY 1025662 ([prop-14C]BAY 1025662) showed that 30.4% of radioactivity was excreted within 1 week and 79.1% by Day 168 (primarily in urine). The terminal half-life of radioactivity elimination was approximately 24 days in blood and plasma and was 31-68 days in the majority of other organs up to Day 168. Elimination was nearly complete at the end of the experiment on Day 168; only ~4% of residual radioactivity was present in the animal body. There was no irreversible binding of radioactivity to any tissues and no penetration of the blood-brain barrier. Based on these results, very low steady-state concentrations of 60-kDa PEG were predicted in patients treated with BAY 94-9027, and the validity of these predictions was supported by clinical studies in which almost all 179 patients receiving BAY 94-9027 for prophylaxis had undetectable PEG in plasma for up to >5 years; those with detectable PEG levels demonstrated concentrations within the predicted range. These combined preclinical and clinical observations suggest that excretion processes are in place for high-molecular-weight PEGs such as the PEG-60 moiety used in BAY 94-9027." @default.
• W2910443668 created "2019-01-25" @default.
• W2910443668 creator A5019087013 @default.
• W2910443668 creator A5035627251 @default.
• W2910443668 creator A5041017593 @default.
• W2910443668 creator A5043091724 @default.
• W2910443668 creator A5074452979 @default.
• W2910443668 creator A5091881925 @default.
• W2910443668 date "2019-03-01" @default.
• W2910443668 modified "2023-09-24" @default.
• W2910443668 title "Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction" @default.
• W2910443668 cites W1552409234 @default.
• W2910443668 cites W1897770000 @default.
• W2910443668 cites W1971728321 @default.
• W2910443668 cites W1977467418 @default.
• W2910443668 cites W1981273187 @default.
• W2910443668 cites W2000597410 @default.
• W2910443668 cites W2009396890 @default.
• W2910443668 cites W2010506651 @default.
• W2910443668 cites W2035362383 @default.
• W2910443668 cites W2055899061 @default.
• W2910443668 cites W2059843712 @default.
• W2910443668 cites W2084587462 @default.
• W2910443668 cites W2090145179 @default.
• W2910443668 cites W2101594010 @default.
• W2910443668 cites W2120293249 @default.
• W2910443668 cites W2126061397 @default.
• W2910443668 cites W2156492800 @default.
• W2910443668 cites W2163797066 @default.
• W2910443668 cites W2166171010 @default.
• W2910443668 cites W2172059708 @default.
• W2910443668 cites W2179446546 @default.
• W2910443668 cites W2291150896 @default.
• W2910443668 cites W2291288111 @default.
• W2910443668 cites W2600573509 @default.
• W2910443668 cites W2604999345 @default.
• W2910443668 cites W2732986568 @default.
• W2910443668 cites W2793056460 @default.
• W2910443668 cites W2979583219 @default.
• W2910443668 doi "https://doi.org/10.1016/j.ejps.2019.01.015" @default.
• W2910443668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30654111" @default.
• W2910443668 hasPublicationYear "2019" @default.
• W2910443668 type Work @default.
• W2910443668 sameAs 2910443668 @default.
• W2910443668 citedByCount "26" @default.
• W2910443668 countsByYear W29104436682019 @default.
• W2910443668 countsByYear W29104436682020 @default.
• W2910443668 countsByYear W29104436682021 @default.
• W2910443668 countsByYear W29104436682022 @default.
• W2910443668 countsByYear W29104436682023 @default.
• W2910443668 crossrefType "journal-article" @default.
• W2910443668 hasAuthorship W2910443668A5019087013 @default.
• W2910443668 hasAuthorship W2910443668A5035627251 @default.
• W2910443668 hasAuthorship W2910443668A5041017593 @default.
• W2910443668 hasAuthorship W2910443668A5043091724 @default.
• W2910443668 hasAuthorship W2910443668A5074452979 @default.
• W2910443668 hasAuthorship W2910443668A5091881925 @default.
• W2910443668 hasBestOaLocation W29104436681 @default.
• W2910443668 hasConcept C10138342 @default.
• W2910443668 hasConcept C10146269 @default.
• W2910443668 hasConcept C112705442 @default.
• W2910443668 hasConcept C126322002 @default.
• W2910443668 hasConcept C134018914 @default.
• W2910443668 hasConcept C162324750 @default.
• W2910443668 hasConcept C178790620 @default.
• W2910443668 hasConcept C185592680 @default.
• W2910443668 hasConcept C2776964284 @default.
• W2910443668 hasConcept C2779149719 @default.
• W2910443668 hasConcept C29730261 @default.
• W2910443668 hasConcept C3941253 @default.
• W2910443668 hasConcept C54400483 @default.
• W2910443668 hasConcept C55493867 @default.
• W2910443668 hasConcept C71924100 @default.
• W2910443668 hasConcept C98274493 @default.
• W2910443668 hasConceptScore W2910443668C10138342 @default.
• W2910443668 hasConceptScore W2910443668C10146269 @default.
• W2910443668 hasConceptScore W2910443668C112705442 @default.
• W2910443668 hasConceptScore W2910443668C126322002 @default.
• W2910443668 hasConceptScore W2910443668C134018914 @default.
• W2910443668 hasConceptScore W2910443668C162324750 @default.
• W2910443668 hasConceptScore W2910443668C178790620 @default.
• W2910443668 hasConceptScore W2910443668C185592680 @default.
• W2910443668 hasConceptScore W2910443668C2776964284 @default.
• W2910443668 hasConceptScore W2910443668C2779149719 @default.
• W2910443668 hasConceptScore W2910443668C29730261 @default.
• W2910443668 hasConceptScore W2910443668C3941253 @default.
• W2910443668 hasConceptScore W2910443668C54400483 @default.
• W2910443668 hasConceptScore W2910443668C55493867 @default.
• W2910443668 hasConceptScore W2910443668C71924100 @default.
• W2910443668 hasConceptScore W2910443668C98274493 @default.
• W2910443668 hasFunder F4320307771 @default.
• W2910443668 hasLocation W29104436681 @default.
• W2910443668 hasLocation W29104436682 @default.
• W2910443668 hasOpenAccess W2910443668 @default.
• W2910443668 hasPrimaryLocation W29104436681 @default.
• W2910443668 hasRelatedWork W1893200055 @default.
• W2910443668 hasRelatedWork W1897820813 @default.
• W2910443668 hasRelatedWork W1985769331 @default.

• next